Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer

被引：54
|
作者：
Hasegawa, Takahiro [1 ]
Uno, Hajime [2 ]
Wei, Lee-Jen [3 ]
机构：
[1] Shionogi, Osaka, Japan
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Harvard Univ, Boston, MA 02115 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2016年 / 374卷 / 05期
关键词：
D O I：
10.1056/NEJMc1514790
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：492 / 492
页数：1
相关论文
共 50 条
  • [1] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Borghaei, H.
    Paz-Ares, L.
    Horn, L.
    Spigel, D. R.
    Steins, M.
    Ready, N. E.
    Chow, L. Q.
    Vokes, E. E.
    Felip, E.
    Holgado, E.
    Barlesi, F.
    Kohlhaeufl, M.
    Arrieta, O.
    Burgio, M. A.
    Fayette, J.
    Lena, H.
    Poddubskaya, E.
    Gerber, D. E.
    Gettinger, S. N.
    Rudin, C. M.
    Rizvi, N.
    Crino, L.
    Blumenschein, G. R.
    Antonia, S. J.
    Dorange, C.
    Harbison, C. T.
    Finckenstein, F. Graf
    Brahmer, J. R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17): : 1627 - 1639
  • [2] Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer
    Keating, Gillian M.
    DRUGS, 2016, 76 (09) : 969 - 978
  • [3] Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer
    Gillian M. Keating
    Drugs, 2016, 76 : 969 - 978
  • [4] Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer
    Bersanelli, Melissa
    Tiseo, Marcello
    Banna, Giuseppe L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (09): : 874 - 875
  • [5] Effect and biomarker of Nivolumab for non-small-cell lung cancer
    Wang, Li
    Zhao, Deze
    Qin, Kang
    Ul Rehman, Faisal
    Zhang, Xiaochun
    BIOMEDICINE & PHARMACOTHERAPY, 2019, 117
  • [6] Perioperative Nivolumab and Chemotherapy in Non-Small-Cell Lung Cancer
    Verma, Saurav
    Vincent, Mark
    Breadner, Daniel
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (16): : 1534 - 1534
  • [7] Nivolumab plus ipilimumab in non-small-cell lung cancer
    Reck, Martin
    Borghaei, Hossein
    O'Byrne, Kenneth J.
    FUTURE ONCOLOGY, 2019, 15 (19) : 2287 - 2302
  • [8] Nivolumab in non-small-cell lung cancer with EGFR mutation
    Yoshida, H.
    Kim, Y. H.
    Ozasa, H.
    Nagai, H.
    Sakamori, Y.
    Tsuji, T.
    Nomizo, T.
    Yasuda, Y.
    Funazo, T.
    Hirai, T.
    ANNALS OF ONCOLOGY, 2018, 29 (03) : 777 - 778
  • [9] Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer
    Sugawara, S.
    Lee, J-S
    Kang, J-H
    Kim, H. R.
    Inui, N.
    Hida, T.
    Lee, K. H.
    Yoshida, T.
    Tanaka, H.
    Yang, C-T
    Nishio, M.
    Ohe, Y.
    Tamura, T.
    Yamamoto, N.
    Yu, C-J
    Akamatsu, H.
    Namba, Y.
    Sumiyoshi, N.
    Nakagawa, K.
    ANNALS OF ONCOLOGY, 2021, 32 (09) : 1137 - 1147
  • [10] Nivolumab for squamous-cell non-small-cell lung cancer
    Yaqub, Farhat
    LANCET ONCOLOGY, 2015, 16 (07): : E319 - E319
12345